Skip to content

Earnings call

Sun Pharmaceutical Industries Q4 FY25 earnings call: Sun Pharma expects mid to high single digit consolidated topline growth for FY'26

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Sun Pharma expects mid to high single digit consolidated topline growth for FY'26. Sun Pharma is planning a trial of GL0034 in type 2 diabetes as its first indication. Sun Pharma's growth was at least 3%-4% higher than the market this year, and the growth came from volume and new product. Sun Pharma is looking to invest approximately US$ 100 million additionally on commercialization of new Specialty product for the current year.

The numbers management gave

Results

  • Sun Pharma's growth was at least 3%-4% higher than the market this year, and the growth came from volume and new product.
    Show source
    So this year our growth is at least 3%-4% higher than the market and the growth is coming from volume and new product.
  • Sun Pharma's full-year figure was 16.6 last year and 19.8 this year; the figure could inch up from the current level because of tax losses.
    Show source
    What I said is that it will inch up I said compared to the last year if you see our full year was 16.6, this year is 19.8.

Money and capital

  • Sun Pharma is looking to invest approximately US$ 100 million additionally on commercialization of new Specialty product for the current year.
    Show source
    For the current year, we are looking to invest approximately US$ 100 million additionally on commercialization of new Specialty product.

What it expects ahead

What management expects

  • Sun Pharma expects mid to high single digit consolidated topline growth for FY'26.
    Show source
    And lastly, on the guidance of FY'26, we expect mid to high single digit consolidated topline growth for FY'26.
  • Sun Pharma's guidance is 6% to 8% because some potential studies are likely to be started.
    Show source
    But some of them will be and that is the reason why we have this 6% to 8% guidance.
  • Sun Pharma expects its growth momentum to continue but cannot predict what its growth will be in coming years. Replaced by a later filing.
    Show source
    I strongly believe we have a good base and then the momentum should continue but we can't predict what this growth will be in coming years.

What it is building and selling

Projects and capacity

  • Sun Pharma is planning a trial of GL0034 in type 2 diabetes as its first indication.
    Show source
    Other change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication.
  • A new source will take at least 2.5 -3 years to be approved by the agency.
    Show source
    I my view is that it will take at least 2.5 -3 years before the new source is approved by the agency.

Everything else said on the call

Group structure

  • Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology; the transaction is awaiting approval and subsequent closing.
    Show source
    Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology.
  • Checkpoint Therapeutics has recently received USFDA approval for UNLOXCYT for metastatic or locally advanced cutaneous squamous cell carcinoma.
    Show source
    Checkpoint has recently received approval from USFDA for UNLOXCYT for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to UNLOXCYT.

People and governance

  • Jayashree Satagopan has joined Sun Pharma and will assume the role of Global Chief Financial Officer effective from 1st of July; C. S. Muralidharan will be superannuating from this role.
    Show source
    Ms. Jayashree Satagopan has joined Sun Pharma and will assume her role as Global Chief Financial Officer effective from 1st of July.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: Hi, good evening. Thank you for the opportunity. First question on the Global Specialty sales growth for the quarter. This is after many quarters we have seen a single digit topline growth in this business. And I think the quarter four base from last year was also a little lower because of the issues at United Healthcare. So is there any one off why we are seeing this kind of lower growth in this quarter? Because sometimes branded companies do see some rebate adjustment, etc. which could lead to this kind of growth. So any color there would be helpful.

    Answer, abhay gandhi

    Abhay Gandhi: I can only speak for the US, Kunal. But Jan and Feb typically are lighter months in the US because of change in the way the insurance resets happens. But otherwise, when I look at the prescription trends and the inventory trends that are there in the market, I am comfortable that our key brands will continue to grow.

  2. Question

    Kunal Dhamesha: So any particular product that you want to call out or is it a broad base you said is more like a seasonality, Jan-Feb which would have paid off?

    Answer, abhay gandhi

    Abhay Gandhi: It's not really a seasonality, Kunal. It's more to go with insurance resets. No particular product that I can call out.

  3. Question

    Kunal Dhamesha: Okay, sure. And second one on the 100 million additional spend that we are expecting this year to spend. The whole idea of getting more dermatology products was to kind of reduce, gain more synergies of our front-end infra which is already in the place. I'm just a little bit confused as to why do we need such a big amount even if we launch two products in dermatology and derma onco which is something that we have already been doing for quite some time Dilip Shanghvi: I think it's a question of looking at how other companies, even very large companies have a significant launch cost for new products.

    Answer, dilip shanghvi

    So once you study, I think this actually is a conservative number.

  4. Question

    Kunal Dhamesha: Okay and sir this is launch cost so in the future it should basically moderate right that's the way we should look at it?

    Answer, dilip shanghvi

    Dilip Shanghvi: Which is what I said is that we don't actually look at this as a cost we look at this as an investment and we expect this to further help us strengthen our Specialty business.

  5. Question

    Damayanti Kerai: Hi, thank you for the opportunity. My question is on Leqselvi. So now, what are the plans for launch of this product in the US? If you can give us some timeline there?

    Answer, abhay gandhi

    Abhay Gandhi: So I think in the quarter two, we will be launching this product in the US. Damayanti Kerai: Second quarter of this fiscal?

  6. Question

    Damayanti Kerai: Okay. And my second question is on your generic business in the US, where you mentioned there was some price pressure, etc. So two things, had it worsened compared to r ecent quarter in the base portfolio. And also if you can comment in the fourth quarter was Revlimid a significant contributor?

    Answer, abhay gandhi

    Abhay Gandhi: I will start with your latter question. I mean Revlimid sales in the Q4 was similar to Q3, and that was not very significant. On pricing, I think we have consistently said that it's product -specific thing, and nothing which I can speak to on a generalized basis. So product -specific, we continue to see pressure on pricing.

  7. Question

    Damayanti Kerai: Okay. It's product -to-product and nothing we should read as part of the change in industry which might have happened on the pricing part.

    Answer, abhay gandhi

    Abhay Gandhi: There is not much which has changed as far as overall industry dynamics is concerned. Basically, it remains the same, that is what we have seen in the past.

  8. Question

    Neha Manpuria: Yes, thanks for taking my question. Abhay, first question on the Checkpoint asset. What should we think about from a timeline perspective for the launch of the product? Obviously, the deal needs to be completed, so will that be a launch probably in the later part of the year?

    Answer, abhay gandhi

    Abhay Gandhi: I think we have to wait for the acquisition to go through all the clearances. And before that, it won't be fair to give an answer on when we will launch. So I think we will actually wait for the processes to get over before I'm able to answer that question. Maybe on the next call, I will be able to. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Neha Manpuria: Fair enough.

  9. Question

    That's clear. My second question is on the India business. We saw a fantastic growth this year, given what the industry has been doing. Kirti, sir, when we think about next year, do we need to invest more in MR? Should the growth momentum that we have seen this year continue? Any color that we can provide on how we are thinking about the India business and the investments there?

    Answer, kirti ganorkar

    Kirti Ganorkar: No, I have been telling for the last couple of calls is we want to grow higher than the market. And that's the effort we are continuously putting quarter-after-quarter. So this year our growth is at least 3%-4% higher than the market and the growth is coming from volume and new product. I strongly believe we have a good base and then the momentum should continue but we can't predict what this growth will be in coming years. It's very difficult.

  10. Question

    Neha Manpuria: And any MR expansion plans for the growth?

    Answer, kirti ganorkar

    Kirti Ganorkar: No, it's like a strategic lever what we said whenever we had done expansion it has helped us to grow. Depending on the opportunity which may come, we will decide on the expansions.

Show 22 more questions
  1. Question

    Anubhav Agarwal: Yes. Hi, guys. One, just trying to understand this $100 million additional spend. So it will be multiple areas that we will be spending on. just checking, is there a dominant part that you guys will be spending on? So what I'm trying to ask is, you guys not been doing TV ads right now? Would you start doing TV ads for the new one? Or how much of this, let's say roughly, is going in expanding the infrastructure on the ground? Let's say more sales force versus more promotion. So what will be a rough split of salesforce expense versus the promotions expense out of this $100 million?

    Answer, abhay gandhi

    Abhay Gandhi: The products that we are talking about are niche areas Anubhav. So they do not lend themselves to TV advertising clearly. So the promotion will be more with the HCPs as well as the patient advocacy groups. Later on as we evolve, we will keep evaluating what works best for the product.

  2. Question

    Anubhav Agarwal: And Abhay the spend will be largely more tilted towards the promotion rather than adding more people on the ground? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Abhay Gandhi: It will be a combination.

    Answer, abhay gandhi

    There will be certain expenses related to optimizing the field force, looking at the target audience that we need to cover, and also looking at competitive dynamics and how your competitors are structured. Large part will, of course, be the variable promo spend.

  3. Question

    Anubhav Agarwal: Okay, that's helpful. Second question is for Dilip bhai. I'm just trying to understand one thing that current manufacturing for the branded product is out, Sun doesn't manufacture directly, most of them, and gets them contract manufactured. So let's say th e tariffs, no one knows what number will come out for tariffs, but just trying to understand that how much, just as a process, how much time does it take if you need to shift manufacturing from outside US to US, from one contract manufacturer to the other contract manufacturer? So the question one is on time. Secondly, what's the harm in Sun Pharma already starting the process now, given what the US wants to do it, etc. So

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think it's a good suggestion. You have to keep one thing in perspective that Ilumya is a biological and transferring a biological product and giving the kind of quantities that we require is not something that is easy to identify a CDMO who can do that in the US. So, we are looking at it because it's not a question of where we feel finished. We will have to manufacture the full product in the US, starting with the active substance.

  4. Question

    Anubhav Agarwal: One part of the questio n was that if you were to do it, how much time does it take if you want to transfer the full product?

    Answer, dilip shanghvi

    Dilip Shanghvi: I think both cost and time. I my view is that it will take at least 2.5 -3 years before the new source is approved by the agency. And it c ost a lot of money.

  5. Question

    Shashank Krishnakumar: Hi. Thanks for taking my question. My first question was on Ilumya. I think our partner in Europe has commercialized 200 mg version there. Just wanted to understand the thought process and if we have plans to also sort of commercialize it in the US market?

    Answer, abhay gandhi

    Abhay Gandhi: I think on the Europe part, you can, sir. In US, we are evaluating for the filing and then subsequently launching the product, but it will take some time.

  6. Question

    Shashank Krishnakumar: Got it. And secondly, on MM-II, I think we have passed Phase-2, and I think we also have a fast-track designation here. I just wanted to understand why we are looking to sort of enter into a partnership to commercialize this? Is it largely because it doesn't fall within a broader Onco-Derma framework? Or why this change in the commercialization strategy?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think you said it's right, is that it doesn't kind of fit immediately into a focus in the US. Because I think we further strengthening our presence in the Dermatology, we continue to look at opportunities in Ophthalmology. Shashank Krishnakumar: Got it, sir. Thank you. That's it from me.

  7. Question

    Vivek Agarwal: The question is related to Leqselvi, the launch seems to have been delayed by 3 -4 quarters because of the litigation, etc. So does anything change from this delay, let's say your expectations from this competitive dynamics or are your expectations on the pro duct are more or less same, let's you would have launched the product last year?

    Answer, abhay gandhi

    Abhay Gandhi: We still believe we have a competitive product. However, since the launch is delayed by, as I said, 3 quarters, I think the time to our expected peak will move a little . But I think the intent of the team will be to try and make up for that lost time by increasing the focus on the product and the investment on the product to try and mitigate it to the extent that we can. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Vivek Agarwal: Thanks, the second question is related to the recent acquisition on UNLOXCYT.

  8. Question

    So if I was looking at some of the competitive products, UNLOXCYT has a bit longer infusion, it is around 60 minutes. They don't have other indications, etc., While if you look at some of the other competing products like Libtayo well- entrenched with the market, longer clinical history, wider indication, so just trying to understand why the prescribers would shift to the new therapy UNLOXCYT, if you can help us understand? Thank you.

    Answer, abhay gandhi

    Abhay Gandhi: Two ways of looking at the whole thing while you we were right that your competitors will have multiple indications and we will end up with only one indication. And that also means that we will be able to give our attention and time to one single indication and try and be the best we can in the arena that we compete in. It helps us focus also better. So you can look at it either way. We look at it of course clearly, but it helps us focus better. Also don't forget in the same indication or rather with the same customer group, we have two other products that we go to. So we have familiarity with the customer groups.

    Answer, abhay gandhi

    Some of course will be new to us, but we understand the space and that also helps.

  9. Question

    Vivek Agarwal: Understood, sir. Thank you. That's from my side.

    Answer, abhay gandhi

    Abhay Gandhi: Yes, that's true. Bino: Okay. And second, this 100 million additional spends that you would do, how should we look at it? You will have a normal selling SG&A expense on which you will have a normal increase which happens every year. On top of that there will be an additional 100 million. Is that the way we can model it? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Dilip Shanghvi: That's correct.

    Answer, dilip shanghvi

    I think we don't want only look at the normal expenses. We got to understand that there are significant launch related costs for these products and it needs to be factored. We don't want to negatively surprise investors afterwards. Bino: And finally, there is a tax rate which has gone up significantly compared to last few years at 19% this year, consolidated level. Is that a new range we should look at for tax or is there some reason why it is high this year?

    Answer, c muralidharan

    C. S. Muralidharan: So we have indicated in earlier communications also that the tax rates continue to inch or go up. Mainly due to this year, we have also said that utilization of the past losses we exhausted. That's one of the primary reasons for the increase in tax rate. Bino: Okay, so practically this is roughly the range that we should expect going forward. Okay, thank you very much.

    Answer, c muralidharan

    C. S. Muralidharan: Bino, just one second. What I said is that it will inch up I said compared to the last year if you see our full year was 16.6, this year is 19.8. That's because of the tax losses it could inch up from the current level. Bino: Got it. Thank you very much.

    Answer, dilip shanghvi

    Dilip Shanghvi: I think broadly our understanding is that in the class it has possibly the safest side effect profile. Girish: So, Dilip bhai, if I just actually ask a bit of generic question here, given this is PD-L1, others are PD-1. Is there a difference for clinicians materially? I don't know if it has been observed in a clinical setting or in other cancers. Does that give a material edge to your asset?

    Answer, abhay gandhi

    And yes, my expression, which you can't see is similar to Dilip bhai, but whatever modeling we have done so far, I mean, there will be an impact, but we think it will be a small impact and the product can continue to be a growth driver in the existing therapy as well as with the new indication that we will get. Girish: Would biosimilars, let's say, impact differently in medical channel versus commercial directly?

    Answer, abhay gandhi

    Abhay Gandhi: So it's a narrower competitive field. So to that extent it helps. Now how much is something that we need to continuously evaluate because there is only so much that you can estimate with a great degree of certainty. Girish: Right. Abhay, do you have any number like how much biosimilar conditions should there be, let's say, 3 years down the line from both these products?

  10. Question

    Tushar Manudhane: Yes, thanks for the opportunity, Sir just with respect to, firstly, on the R&D spend guidance of 6% to 8%, so does this factor the R&D spend, additional or higher R&D spend on the existing projects, or are we building new projects for the R&D spend basically? That's my first question.

    Answer, dilip shanghvi

    Dilip Shanghvi: It includes everything. It does not include transactions that we have not done. If there is a transaction that we do in future during the year, then that can change the guidance. But this includes whatever that we have in the pipeline.

  11. Question

    Tushar Manudhane: Got it. And sir secondly, with the growth in let's say branded markets of India, Emerging Markets, and the Specialty, and at the same time spending on the Specialty product, how to think about the EBITDA growth compared to revenue growth for FY'26?

    Answer, dilip shanghvi

    Dilip Shanghvi: Generally, we don't give margin guidance. That is why because we felt that analysts would not have clarity about increased cost of launching the product, we give a specific number which helps the model but we don't give margin guidance. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Tushar Manudhane: Okay, sir.

  12. Question

    Anubhav Agarwal: Yes, thank you. Just trying to understand the impact of new MFN laws on Sun Pharma. So please help me understand if this is an important metric to look at. If on the Medicare side, would they look at price difference between Ilumya in the US and Ilumetri in Europe and then try to compare the two and ask you guys to let's say match those prices, one. That's first part of the question. Second, is there a material difference between the price of Ilumya and Ilumetri?

    Answer, dilip shanghvi

    Dilip Shanghvi: I think we have to wait for greater clarity on finally how this... because as I read it, it is kind of currently at a voluntary level. So we have no idea as to how it plays out. So we have to wait for greater clarity before we respond. To the question of the price difference between the US and Europe, I think all the branded products will have significant difference in the prices between US as well as Europe. I mean this is not only our product, all the products. Only thing we have to keep in perspective is that it for any reason I don't understand but stock prices of big pharma companies have not changed.

  13. Question

    Anubhav Agarwal: Just one technical clarity on this like Sun is selling Ilumya in the US but Sun technically is not selling in Europe. So does it…?

    Answer, dilip shanghvi

    Dilip Shanghvi: There are many issues that we can go into. So, till the time we have clarity on finally how the law is because this is just a what you call guidance document without specific how it will be implemented and on what condition, what provision. Because if you see the IRA when they wanted to implement, they gave a significant amount of time and very great level of clarity as to how, what, what is negotiation, how it will be done. So that level of clarity doesn't exist here.

  14. Question

    Anubhav Agarwal: One question on the cash. So the company is carrying $3 billion cash is there. And almost generating more than a billion-dollar free cash flow. So all the acquisitions that you made so far in the last few years, they were less than the free cash flow companies were generating and you not been using the cash pile. So just trying to understand here, what is eventual use, would someday you will end up doing a very large acquisition you will use the cash, otherwise your free cash flow is so large that you're not acquiring to that extent.

    Answer, dilip shanghvi

    Dilip Shanghvi: I think we have always consistently maintained that we continue to look at acquisitions which will help us create value. Because any business that we acquire, should be able to run it significantly better than the current owners. Or we should have significant potential synergies. Otherwise it will not justify the acquisition premium.

  15. Question

    Anubhav Agarwal: So would you be look out for a large equation at some point of time, not the timeline. But if you get an opportunity like that, even if it's a large platform, you would be able to…?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, with our Ranbaxy experience, we will also look at our ability to manage. Because anything that we do, should then be able to manage and manage it well. But size is not something which would kind of put us off. We are open to do it, but more important it has to be strategic. And multiple other, what I would call, checklists it needs to go through.

  16. Question

    Kunal Dhamesha: Hi, thanks for the opportunity again. Couple of question on Unloxcyt. Abhay, would you say that Ilumya's current prominent case standard in the US could also be the primary channel for Unloxcyt?

    Answer, abhay gandhi

    Abhay Gandhi: Sorry, I'm not clear on the question. Ilumya and Unloxcyt are in two different spaces.

  17. Question

    Kunal Dhamesha: Right, but the payorr channels, let's say there are peer channels like Medicare Part B, Commercial Medicaid, right? So would you say that Ilumya's prominent channel would also be the Unloxcyt's primary channel for sale, given the…? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Abhay Gandhi: There is some overlap, I think I would not want to characteri

    Answer, abhay gandhi

    There is a buy and bill component, that is where you are going, but that will not be the only one.

  18. Question

    Kunal Dhamesha: Sure. And secondly, since we have Levulan in the portfolio, which is for actinic keratoses, which is a precursor condition for the squamous cell carcinoma. Do you think does that also help us synergistically identify patients versus maybe competition?

    Answer, abhay gandhi

    Abhay Gandhi: Which is what I said when I answered a prior question by another of your peers., that understanding the space and knowing the customers and the conditions will help us definitely. And that is why we are looking at more products in that space to strengthen our franchise as a whole.

  19. Question

    Saion Mukherjee: Alright sir, are these phase 3 studies very expensive? Can you give some color? If you can give some idea about the quantum of spend if you have to do phase 3 studies for these assets?

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean, general answer would be these are long studies and expensive studies. Specific number till we have the negotiation because we have to power the study. For that we have to understand the Phase-2 data with a view to understand how to power. So all of that will help us in designing the study and that. So till we have that clarity, we will not. We would have taken some indicative number for all potential studies which are likely to be started. But some of them will be and that is the reason why we have this 6% to 8% guidance.

  20. Question

    Kunal Lakhan: Yes, hi. Thanks. Good evening. Just on the MFN again, I know you said there's no clarity there on how it will be implemented. But just in the event that it does get implemented, what proportion of the US business would be impacted by this? Will it be like the entire US Specialty portfolio or some part of it?

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean, there is no clarity only. Whether it will apply to Medicare, Medicaid or it will apply to Commercial. So when there is no clarity, how can we give any idea? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY25 Earnings Call Transcript 06:30 pm May 22, 2025 Kunal Lakhan: Okay, alright.

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean there is a statement if you say which says that patient can get access. I don't know how a patient will get access till there is a method by which a patient can claim reimbursement from the insurance company because doctors have a way by which they can claim reimbursement for products in the formulary. So how will this process work? There has to be some clarity.

  21. Question

    Kunal Lakhan: Understood sir. On the investment of 100 million for launch of new products, what would this number have been in FY'25?

    Answer, dilip shanghvi

    Dilip Shanghvi: This we are guiding for extra cost.

  22. Question

    Vivek Agarwal: Okay sir, thank you. That's all from my side.

    Answer, abhishek sharma

    Abhishek Sharma: Before we conclude the call, we would like to share an organizational update. Ms. Jayashree Satagopan has joined Sun Pharma and will assume her role as Global Chief Financial Officer effective from 1st of July. Concurrently, Mr. C. S. Muralidharan will be superannuating from this role. On this occasion, we extend our sincere appreciation to Mr. Muralidharan for his unwavering commitment and distinguished leadership throughout his tenure with Sun Pharma. Thank you and have a good day.

Questions about this call

When was the Sun Pharmaceutical Industries Q4 FY25 earnings call transcript filed?
Sun Pharmaceutical Industries filed the transcript with the exchange on 29 May 2025. This page is built from that transcript.
What does this page list?
11 statements from the transcript across 6 topics, 8 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 32 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Sun Pharmaceutical Industries Q4 FY25 concall: Sun Pharma expects mid to high single digit consolidated topline growth for FY'26 · DalalOS